TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30196397

Group type: EXPERIMENTAL
Intervention: MDMA (75 to 125 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 12
Study: 26753808

Group type: EXPERIMENTAL
Intervention: Bypass to the nearest neuroscience centre (NC)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Selective secondary transfer to NSAH
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: 30-day mortality
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: 6-month Extended Glasgow Outcome Scale (GOSE)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: European Quality of Life-5 Dimensions
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Pathway acceptability to patients, families, and staff
Number of subjects: 293
Study: 24147757

Group type: EXPERIMENTAL
Intervention: Stop-signal training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dieting implementation intentions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 22647800

Group type: EXPERIMENTAL
Intervention: 10-session educational program, 'Celiac School', based on problem-based learning
Number of subjects: 106

Group type: COMPARATOR
Intervention: Information regarding celiac disease sent at home
Number of subjects: 106
Study: 19383986

Group type: EXPERIMENTAL
Intervention: Compounded omeprazole
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Manufactured omeprazole
Number of subjects: 30
Study: 17725245

Group type: EXPERIMENTAL
Intervention: DEX 960 mg
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: DEX 1,920 mg
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 114
Study: 16038522

Group type: EXPERIMENTAL
Intervention: Amoxicillin/sulbactam
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 62
Study: 12048095

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (group I) with continuous infusion of bupivacaine 0.125% and 2mg fentanyl/ml at a dosage of 6-10 ml per hour for 5 days.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intercostal nerve block (group II) with 20 ml 0.5% bupivacaine applied at the end of the operation.
Number of subjects: 30
Study: 10401013

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol-grafted cellulose (PGC) membranes
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cuprophane membranes
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both membranes (PGC and cuprophane)
Number of subjects: 63
Study: 7743697

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (enalapril)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasodilator therapy (hydralazine/isosorbide dinitrate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2106369

Group type: EXPERIMENTAL
Intervention: Periodic breast cancer screening with mammography and clinical examination
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60000
Study: 6166347

Group type: EXPERIMENTAL
Intervention: Polysaccharide group (semisynthetic polysulphated xylan)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Dextran 70 group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study: 31328363

Group type: EXPERIMENTAL
Intervention: GLP-1 antagonist exendin 9-39
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gastric emptying study
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 40
Study: 28344139

Group type: EXPERIMENTAL
Intervention: Worsening renal function (defined as a >20% reduction in estimated glomerular filtration rate from discharge to 6 months, or progression to macroalbuminuria)
Number of subjects: 2776

Group type: COMPARATOR
Intervention: Stable renal function
Number of subjects: 2776

Group type: EXPERIMENTAL
Intervention: Worsening renal function
Number of subjects: 2776
Study: 26509639

Group type: EXPERIMENTAL
Intervention: Mucopolysaccharide hemospheres (MPH)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC) gel
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Potato starch wafer
Number of subjects: 48
Study: 24722351

Group type: EXPERIMENTAL
Intervention: 4CMenB
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: rMenB
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 4CMenB (40 and 42 months)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (before immunization)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (after immunization)
Number of subjects: 49
Study: 23047822

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg intravenously at days 1 and 15, plus standard chemotherapy)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Standard chemotherapy (3 + 7)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg intravenously at days 1 and 15, plus cytarabine 1000 mg/m(2) twice daily on days 1‐6)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Bevacizumab arm
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 171
Study: 19571250

Group type: EXPERIMENTAL
Intervention: 12‐hr tobacco deprivation (n = 51)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Ad libitum smoking (n = 69)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: 12‐hr tobacco deprivation
Number of subjects: 212

Group type: COMPARATOR
Intervention: Ad libitum smoking
Number of subjects: 212
Study: 17304449

Group type: EXPERIMENTAL
Intervention: Sb(v) plus oral pentoxifylline for 30 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sb(v) plus oral placebo
Number of subjects: 23
Study: 15193908

Group type: EXPERIMENTAL
Intervention: 10-min exercise break involving moderate intensity, low-impact aerobic dance and calisthenic movements to music
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: 10-min exercise break
Number of subjects: 449

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 449
Study: 11515595

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9609365

Group type: EXPERIMENTAL
Intervention: Parental history of hypertension
Number of subjects: 3250

Group type: EXPERIMENTAL
Intervention: Parental history of diabetes
Number of subjects: 3250

Group type: COMPARATOR
Intervention: Parental hypertension
Number of subjects: 3250

Group type: COMPARATOR
Intervention: Proliferative retinopathy
Number of subjects: 3250
Study: 8001358

Group type: EXPERIMENTAL
Intervention: Social support intervention with a minimum of four visits at home by a trained health worker providing emotional support and health education.
Number of subjects: 2235

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 2235
Study: 3281387

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Adjuvant-only preparation
Number of subjects: 35
Study: 5317541

Group type: COMPARATOR
Intervention: Metaproterenol aerosol (0.65 mg per dose, taken as required several times daily)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Metaproterenol aerosol (average treatment duration of about four months)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Metaproterenol oral tablets (20 to 80 mg daily for an average of about three weeks)
Number of subjects: 134
Study: 31838056

Group type: EXPERIMENTAL
Intervention: Framing statement: severe, life-threatening
Number of subjects: 1961

Group type: EXPERIMENTAL
Intervention: Framing statement: serious
Number of subjects: 1961

Group type: EXPERIMENTAL
Intervention: Framing statement: basic
Number of subjects: 1961
Study: 31465685

Group type: EXPERIMENTAL
Intervention: Short-term storage red cells
Number of subjects: 1693

Group type: COMPARATOR
Intervention: Long-term storage red cells
Number of subjects: 1693
Study: 28844039

Group type: EXPERIMENTAL
Intervention: External stressors (radio noise and a distractive scripted family member)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition (no external stressors)
Number of subjects: 30
Study: 26152418

Group type: EXPERIMENTAL
Intervention: Emodepside/Praziquantel solution (3 mg/kg emodepside and 12 mg/kg praziquantel)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo spot-on (control group)
Number of subjects: 16
Study: 21884030

Group type: EXPERIMENTAL
Intervention: R-BNP
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: COMPARATOR
Intervention: Levosimendan
Number of subjects: 11
Study: 21522069

Group type: EXPERIMENTAL
Intervention: Chocolate Milk (CM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 19025665

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 16527396

Group type: EXPERIMENTAL
Intervention: High-intensity electroacupuncture (to tolerance but sub-noxious)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo electroacupuncture (using Streitberger placebo needle)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no electrical stimulation, placebo needles)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-intensity electroacupuncture (strong but comfortable)
Number of subjects: 48
Study: 12881011

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Mixture (vitamin C, vitamin E, and a-lipoic-acid)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 10792132

Group type: EXPERIMENTAL
Intervention: Lightwand-guided intubation through the intubating laryngeal mask airway
Number of subjects: 120

Group type: COMPARATOR
Intervention: Blind intubation through the intubating laryngeal mask airway
Number of subjects: 120
Study: 9495936

Group type: EXPERIMENTAL
Intervention: Enzymatic rinse
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control rinse
Number of subjects: 15
Study: 7680732

Group type: EXPERIMENTAL
Intervention: Following-the-child's-lead condition
Number of subjects: 3

Group type: COMPARATOR
Intervention: Recruiting-the-child's-attention condition
Number of subjects: 3
Study: 3485398

Group type: EXPERIMENTAL
Intervention: Intranasal nifedipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intranasal saline
Number of subjects: 20
Study: 30412065

Group type: EXPERIMENTAL
Intervention: On-demand therapy with esomeprazole 40 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Continuous therapy with esomeprazole 20 mg
Number of subjects: 80
Study: 28157463

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Any TB incidence
Number of subjects: 539

Group type: COMPARATOR
Intervention: Any TB incidence before ART initiation
Number of subjects: 539

Group type: COMPARATOR
Intervention: Any TB incidence <180 days after ART initiation
Number of subjects: 539

Group type: COMPARATOR
Intervention: Any TB incidence ≥180 days after ART initiation
Number of subjects: 539
Study: 25546704

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB) or intra-aortic balloon pump (IABP)
Number of subjects: 2525

Group type: EXPERIMENTAL
Intervention: Planned CPB or IABP
Number of subjects: 2525

Group type: EXPERIMENTAL
Intervention: Emergent CPB or IABP
Number of subjects: 2525

Group type: COMPARATOR
Intervention: No CPB or IABP
Number of subjects: 2525
Study: 21744061

Group type: EXPERIMENTAL
Intervention: Structured physical activity intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Aerobic exercises alone (Control Group)
Number of subjects: 140
Study: 19919569

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day combined with peginterferon (Peg‐IFN)‐alpha‐2b/ribavirin (RBV) for 48 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard of care (Peg‐IFN‐alpha‐2b/RBV for 48 weeks)
Number of subjects: 97
Study: 18990058

Group type: EXPERIMENTAL
Intervention: Adenovirus type 5 (Ad5)‐vectored clade B HIV‐1 monovalent gag and trivalent gag/pol/nef vaccines
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Adenovirus type 5 (Ad5)‐vectored clade B HIV‐1 vaccines with >or=1 x 10(10) gag‐containing Ad5 particles per dose
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Adenovirus type 5 (Ad5)‐vectored clade B HIV‐1 vaccines
Number of subjects: 406
Study: 16893966

Group type: EXPERIMENTAL
Intervention: Moderate alcohol dose
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sober participants
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Self-reported sexual arousal influenced by alcohol consumption and expectancies
Number of subjects: 134
Study: 12682876

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (STI571)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon‐alfa (IFN‐alpha)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxyurea (HU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alkylating agents
Number of subjects: 0
Study: 11051345

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.i.d.) for 2 weeks followed by clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) for 1 week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg b.i.d.) for 2 weeks followed by clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) for 1 week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg b.i.d.) for 2 weeks followed by clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) for 1 week
Number of subjects: 30
Study: 9325828

Group type: EXPERIMENTAL
Intervention: Adhesive polymeric film dressing A
Number of subjects: 100

Group type: COMPARATOR
Intervention: Adhesive polymeric film dressing B
Number of subjects: 100
Study: 7902225

Group type: EXPERIMENTAL
Intervention: Cold compression dressings
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no cold compression)
Number of subjects: 90
Study: 3979000

Group type: EXPERIMENTAL
Intervention: Dazoxiben (100 mg, intravenously every 4 hours for a maximum of 72 hours)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (intravenously every 4 hours for a maximum of 72 hours)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dazoxiben
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31594739

Group type: EXPERIMENTAL
Intervention: Sodium phosphate
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Pink lady
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Soap suds
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Other
Number of subjects: 768
Study: 29903505

Group type: EXPERIMENTAL
Intervention: IGRT (arm 1)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: IGRT + HDR (arm 2)
Number of subjects: 57
Study: 26745226

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise for 8 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 81
Study: 24720918

Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg/day
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 22578518

Group type: EXPERIMENTAL
Intervention: Anthracycline chemotherapy (mean dose, 296 ± 103 mg/m²)
Number of subjects: 19
Study: 20880151

Group type: EXPERIMENTAL
Intervention: Propofol loading dose administered over 3.0 min (4 mg·kg(‐1))
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 200 mcg·kg(‐1)·min(‐1) for 5 min or until respiratory insufficiency observed
Number of subjects: 50
Study: 18602657

Group type: EXPERIMENTAL
Intervention: Tasks requiring varied degrees of lexical processing (1-4 words displayed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tasks requiring significant lexical processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tasks that do not require significant lexical processing
Number of subjects: 0
Study: 11322207

Group type: EXPERIMENTAL
Intervention: 5 MU of interferon (IFN) tiw plus ribavirin (1000‐1200 mg/daily) for 12 months
Number of subjects: 192

Group type: COMPARATOR
Intervention: 5 MU of interferon (IFN) tiw monotherapy
Number of subjects: 192
Study: 9130939

Group type: EXPERIMENTAL
Intervention: Hib polysaccharide tetanus protein (PRP-T) mixed with diphtheria-tetanus-pertussis vaccine (DTP)
Number of subjects: 42848

Group type: COMPARATOR
Intervention: DTP alone
Number of subjects: 42848
Study: 8433727

Group type: EXPERIMENTAL
Intervention: Immediate angioplasty
Number of subjects: 108

Group type: COMPARATOR
Intervention: Thrombolytic agent (tissue plasminogen activator)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Immediate angioplasty and thrombolytic agent
Number of subjects: 108
Study: 3314973

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg, 5 times a day for 5 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg and Placebo
Number of subjects: 60
Study: 30029153

Group type: EXPERIMENTAL
Intervention: No Exercise Group (n=19)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Reduced MVPA Group (n=18)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control Group (n=20)
Number of subjects: 57
Study: 27766413

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Converted laparoscopic surgery
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Converted procedures
Number of subjects: 1044
Study: 25996491

Group type: EXPERIMENTAL
Intervention: Primary IOL implantation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Contact lens (no IOL implantation)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Younger age at surgery
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Smaller corneal diameter
Number of subjects: 114
Study: 23937975

Group type: EXPERIMENTAL
Intervention: Stepped-care programme (watchful waiting, guided self-help, problem solving treatment, referral to general practitioner)
Number of subjects: 230
Study: 20562124

Group type: EXPERIMENTAL
Intervention: Azithromycin (n = 40), administered three times a week for 2 years
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Azithromycin (n = 40)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Open-label azithromycin for BOS
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo (n = 43)
Number of subjects: 83
Study: 19040726

Group type: EXPERIMENTAL
Intervention: 5% tea tree oil (TTO) body wash
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard body wash (Johnsons Baby Softwash)
Number of subjects: 0
Study: 16507189

Group type: EXPERIMENTAL
Intervention: Inhalation induction with sevoflurane followed by subhypnotic dose of propofol (1 mg kg‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous propofol induction
Number of subjects: 120

Group type: COMPARATOR
Intervention: Inhalation induction with sevoflurane
Number of subjects: 120
Study: 12748506

Group type: EXPERIMENTAL
Intervention: Intrauterine growth restriction (IUGR) fetuses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-IUGR fetuses
Number of subjects: 0
Study: 11055098

Group type: EXPERIMENTAL
Intervention: Zinc nasal gel (Zicam)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 8927940

Group type: EXPERIMENTAL
Intervention: Modified-release amoxicillin tablet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 6
Study: 1581716

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 29
Study: 31387970

Group type: EXPERIMENTAL
Intervention: Outreach plus $5 incentive
Number of subjects: 8565

Group type: EXPERIMENTAL
Intervention: Outreach plus $10 incentive
Number of subjects: 8565

Group type: EXPERIMENTAL
Intervention: Any incentive (combined $5 and $10)
Number of subjects: 8565

Group type: COMPARATOR
Intervention: Outreach alone
Number of subjects: 8565

Group type: COMPARATOR
Intervention: No incentives
Number of subjects: 8565
Study: 28931127

Group type: EXPERIMENTAL
Intervention: 1 standard dose IM dose of PVRV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1/5th‐fractional dose ID of PVRV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2/5th‐fractional dose ID of PVRV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3/5th‐fractional dose ID of PVRV
Number of subjects: 30

Group type: COMPARATOR
Intervention: All groups after simulated rabies post-exposure prophylaxis (D0, D3) 1 year later
Number of subjects: 30
Study: 26947254

Group type: EXPERIMENTAL
Intervention: Emotion regulation training (n = 25)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No-regulation group (n = 23)
Number of subjects: 48
Study: 25055554

Group type: EXPERIMENTAL
Intervention: Intravenous ozone therapy and small doses of direct current (20-25mkA)
Number of subjects: 89
Study: 22582168

Group type: EXPERIMENTAL
Intervention: Model of continuous and variable resource allocation in VSTM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous models of VSTM (slot models)
Number of subjects: 0
Study: 19225062

Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Exhaled nitric oxide (ENO)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Exhaled breath condensate (EBC) pH
Number of subjects: 31
Study: 18953411

Group type: EXPERIMENTAL
Intervention: Immediate and delayed reaching tasks under non‐masked trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate and delayed reaching tasks under masked trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non‐masked trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Masked trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reaching tasks
Number of subjects: 0
Study: 16186468

Group type: COMPARATOR
Intervention: Conventional treatment with aspirin alone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus colchicine (1.0-2.0 mg the first day and then 0.5-1.0 mg/d for 6 months)
Number of subjects: 84